Showing 2681-2690 of 3069 results for "".
- Bath Emollients Don't Add Much to Standard Eczema Carehttps://practicaldermatology.com/news/bath-emollients-dont-add-much-to-standard-eczema-care/2457784/Emollient bath additives provide no meaningful benefit when used in addition to standard eczema care in children, according to research in the BMJ. UK researchers, led by Miriam Santer, MBBChir
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- News You Can Use: Simple One-Page Tool Improves Patient Satisfaction with Doctor Visithttps://practicaldermatology.com/news/news-you-can-use-simple-one-page-tool-improves-patient-satisfaction-with-doctor-visit/2457805/A simple, one-page form given to patients ahead of time can significantly improve satisfaction with care, according to a study by Duke Health researchers. The low-tech tool, which asks for a list of the topics patients wants to discuss during their visit, helps patients focus on what&rsqu
- Take That, Kim and Kylie : Most Millennials Don't Want Your Advice on Cosmetic Surgeryhttps://practicaldermatology.com/news/take-that-kim-and-kylie/2457812/When it comes to deciding on nips and tucks, millennials are not inclined to trust social media or celebs, a new
- Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjectorhttps://practicaldermatology.com/news/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector/2457966/Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional administration option for appropriate Enbrel patients. T
- Sculpsure Cleared to Treat Double Chinshttps://practicaldermatology.com/news/sculpsure-cleared-to-treat-double-chins/2458036/Cynosure's SculpSure® is now cleared for submental fat reduction. The U.S. Food and Drug Administration (FDA) granted an expanded FDA 510(k) clearance for this area, Hologic, Inc. reports.
- Study: Most Melanomas Don't Arise From Existing Moleshttps://practicaldermatology.com/news/study-most-melanomas-dont-arise-from-existing-moles/2458072/Less than one-third of melanomas (29 percent) arose from an existing mole, while the vast majority (71 percent) appeared on the skin as new spots, according to research in the Journal of the American Academy of Dermatology</
- New Criteria Aims to Help Doctors Spot Amelanotic Melanoma Earlierhttps://practicaldermatology.com/news/new-criteria-aims-to-help-doctors-spot-amelanotic-melanoma-earlier/2458092/New research outlines key features linked to amelanotic melanoma. The findings, which appear in JAMA Dermatology, may help improve detection of this type of melanoma, which is more likely to be diagnosed at advanced stages because it falls outside of the “ABCDE” guide
- Paratek: Phase 3 Study of Oral-Only Dosing of Omadacycline Met FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infectionshttps://practicaldermatology.com/news/paratek-phase-3-study-of-oral-only-dosing-of-omadacycline-met-fda-and-ema-efficacy-endpoints-in-acute-bacterial-skin-infections/2458118/Paratek Pharmaceuticals, Inc. shared positive top-line results from a pivotal Phase 3 study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The study met all of
- ASDS: Percentage of Us Wanting Cosmetic Surgery Doubled Since 2013https://practicaldermatology.com/news/asds-percentage-of-us-wanting-cosmetic-surgery-doubled-since-2013/2458141/Nearly 70 percent of consumers now say they are thinking about getting a cosmetic treatment, according to survey data released by the American Society for Dermatologic Surgery (ASDS). The ASDS Consumer